Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Drops By 5.5%

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 3,420,000 shares, a drop of 5.5% from the December 15th total of 3,620,000 shares. Based on an average daily trading volume, of 426,500 shares, the days-to-cover ratio is presently 8.0 days.

Analyst Ratings Changes

ASND has been the subject of a number of recent research reports. TD Cowen lowered their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. UBS Group began coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Bank of America lifted their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $192.07.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $128.13 on Friday. The stock has a market capitalization of $7.78 billion, a price-to-earnings ratio of -15.86 and a beta of 0.65. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00. The business’s fifty day moving average price is $133.13 and its 200-day moving average price is $133.50.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds have recently bought and sold shares of the stock. Groupama Asset Managment purchased a new stake in Ascendis Pharma A/S in the 3rd quarter worth $60,000. Janus Henderson Group PLC raised its holdings in shares of Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after acquiring an additional 267,881 shares in the last quarter. Avoro Capital Advisors LLC increased its position in Ascendis Pharma A/S by 5.8% in the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP increased its position in Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after purchasing an additional 155,971 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.